[go: up one dir, main page]

BRPI0410702A - polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor - Google Patents

polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor

Info

Publication number
BRPI0410702A
BRPI0410702A BRPI0410702-0A BRPI0410702A BRPI0410702A BR PI0410702 A BRPI0410702 A BR PI0410702A BR PI0410702 A BRPI0410702 A BR PI0410702A BR PI0410702 A BRPI0410702 A BR PI0410702A
Authority
BR
Brazil
Prior art keywords
virus
composition
pathogen
vector
cell
Prior art date
Application number
BRPI0410702-0A
Other languages
English (en)
Inventor
Yoshihiro Kawaoka
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BRPI0410702A publication Critical patent/BRPI0410702A/pt
Publication of BRPI0410702B1 publication Critical patent/BRPI0410702B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"POLINUCLEOTìDEO ISOLADO, COMPOSIçãO, MéTODOS PARA PREPARAR UM VìRUS DE INFLUENZA E UM VEìCULO DE LIBERAçãO DE GENES, E PARA IMUNIZAR UM INDIVìDUO CONTRA UM PATóGENO, VìRUS, CéLULA, E, VETOR". A invenção provê uma composição utilizável para preparar vírus de influenza de titulo elevado, por exemplo na ausência de vírus auxiliar, que inclui uma seqüência de um isolado de vírus de influenza de título elevado.
BRPI0410702-0A 2003-05-28 2004-05-27 Composição, métodos para preparar um vírus de influenza e um veículo de liberação de genes, e, vírus BRPI0410702B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47379803P 2003-05-28 2003-05-28
US60/473,798 2003-05-28
PCT/US2004/016680 WO2004112831A2 (en) 2003-05-28 2004-05-27 High titer recombinant influenza viruses for vaccines and gene therapy

Publications (2)

Publication Number Publication Date
BRPI0410702A true BRPI0410702A (pt) 2006-06-13
BRPI0410702B1 BRPI0410702B1 (pt) 2022-04-12

Family

ID=33539054

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410702-0A BRPI0410702B1 (pt) 2003-05-28 2004-05-27 Composição, métodos para preparar um vírus de influenza e um veículo de liberação de genes, e, vírus

Country Status (19)

Country Link
US (1) US8475806B2 (pt)
EP (1) EP1631663B1 (pt)
JP (2) JP5215561B2 (pt)
KR (1) KR100908757B1 (pt)
CN (1) CN1826407B (pt)
AU (1) AU2004249133B2 (pt)
BR (1) BRPI0410702B1 (pt)
CA (1) CA2525953C (pt)
EA (1) EA012965B1 (pt)
ES (1) ES2593082T3 (pt)
HK (1) HK1082769A1 (pt)
HU (1) HUE030962T2 (pt)
IL (2) IL171831A (pt)
MX (1) MX342639B (pt)
NO (1) NO341506B1 (pt)
NZ (1) NZ543446A (pt)
UA (1) UA92132C2 (pt)
WO (1) WO2004112831A2 (pt)
ZA (1) ZA200510309B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
EA012965B1 (ru) 2003-05-28 2010-02-26 Висконсин Эламни Рисёч Фаундэйшн Композиция для получения реассортантного рекомбинантного вируса гриппа, способ получения указанного вируса и реассортантный рекомбинантный вирус гриппа
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
EP1814990A2 (en) 2004-11-19 2007-08-08 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
BRPI0612268A2 (pt) * 2005-06-21 2009-01-27 Medimmune Vaccines Inc Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
DK1951296T4 (da) 2005-11-01 2014-09-01 Novartis Vaccines & Diagnostic Celleafledte viral vacciner med lave niveauer af restcelle-DNA
KR101484305B1 (ko) * 2006-03-10 2015-01-19 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스
JP2007259758A (ja) * 2006-03-28 2007-10-11 Wisconsin Alumni Research Foundation Ｈ３型ウマａ型インフルエンザウイルス
EP2010557B1 (en) * 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
AU2013204811B2 (en) * 2006-04-19 2015-01-22 Medimmune, Llc Methods and compositions for expressing negative-sense viral rna in canine cells
RU2457250C2 (ru) 2006-04-19 2012-07-27 Медиммуне, Ллк Способы и композиции для экспрессии антисмысловой вирусной рнк в клетках собаки
US20090017444A1 (en) * 2006-06-09 2009-01-15 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
JP2009543554A (ja) 2006-07-14 2009-12-10 サノフィ パスツール バイオロジクス カンパニー ベクターウイルスタンパク質への外来免疫決定基の直接トランスポゾン媒介挿入による組換え型ウイルスワクチンの構築
US20100239605A1 (en) * 2006-09-29 2010-09-23 Sanofi Pasteur Biologics Co. Recombinant Rhinovirus Vectors
EP2146575A4 (en) * 2007-04-12 2010-11-24 Alnylam Pharmaceuticals Inc INFLUENZA POLYNUCLEOTIDES, EXPRESSION CONSTRUCTS, COMPOSITIONS AND METHOD FOR THEIR USE
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20120015346A1 (en) * 2010-07-08 2012-01-19 New York Medical College Influenza virus detection and diagnosis
CA3103774A1 (en) * 2011-06-24 2012-12-27 Flugen, Inc. Influenza virus mutants and uses therefor
JP6054883B2 (ja) * 2012-03-02 2016-12-27 ノバルティス アーゲー インフルエンザウイルスの再集合
JP2013099339A (ja) * 2013-01-04 2013-05-23 Wisconsin Alumni Research Foundation Ｈ３型ウマａ型インフルエンザウイルス
JP2016524915A (ja) * 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
KR101493613B1 (ko) * 2013-10-25 2015-02-13 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스
EP3119883A4 (en) 2014-03-17 2018-01-10 Flugen, Inc. Influenza virus vectors and uses therefor
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2016201127A1 (en) 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
JP6560056B2 (ja) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
RU2660562C2 (ru) * 2016-03-30 2018-07-06 Общество с ограниченной ответственностью "ФАРМИНТЕРПРАЙСЕЗ БИОТЕХ" Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
EP3417056A1 (en) 2016-02-19 2018-12-26 Wisconsin Alumni Research Foundation (WARF) Improved influenza b virus replication for vaccine development
JP2017038622A (ja) * 2016-11-21 2017-02-23 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
EP3700562A1 (en) 2017-10-25 2020-09-02 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
JP2022527235A (ja) 2019-01-23 2022-06-01 義裕 河岡 インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
CN114929269A (zh) * 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
CN118497151B (zh) * 2024-07-11 2024-10-01 昆明理工大学 表达trail的重组溶瘤流感病毒及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
WO1996010400A1 (en) 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
ATE451451T1 (de) 1996-07-15 2009-12-15 Us Gov Health & Human Serv Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
CN1250725C (zh) 1997-05-23 2006-04-12 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
KR100281676B1 (ko) 1997-11-29 2001-04-02 신동권 신규한독감생백신바이러스
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
DE122008000061I1 (de) * 1999-04-06 2009-02-12 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
WO2001079273A2 (en) 2000-04-14 2001-10-25 Wisconsin Alumni Research Foundation Viruses comprising mutated ion channel protein
DK1317559T3 (da) * 2000-04-28 2009-03-23 St Jude Childrens Res Hospital DNA-transfektionssystem til frembringelse af smitsom negativstrenget RNA-virus
EP1201760A1 (en) * 2000-10-30 2002-05-02 ARTEMIS Pharmaceuticals GmbH Influenza virus vector for human dendritic cells
WO2003068923A2 (en) 2002-02-13 2003-08-21 Wisconsin Alumni Research Foundation Signal for packaging of influenza virus vectors
AU2004232992A1 (en) 2003-04-23 2004-11-04 Wisconsin Alumni Research Foundation Recombinant influenza viruses holding a mutation in a transmembrane protein gene
EA012965B1 (ru) 2003-05-28 2010-02-26 Висконсин Эламни Рисёч Фаундэйшн Композиция для получения реассортантного рекомбинантного вируса гриппа, способ получения указанного вируса и реассортантный рекомбинантный вирус гриппа
CN1829799A (zh) 2003-05-28 2006-09-06 威斯康星旧生研究基金会 含polii启动子和核酶的重组流感载体
EP1814990A2 (en) 2004-11-19 2007-08-08 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
EP2010557B1 (en) * 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines

Also Published As

Publication number Publication date
WO2004112831A2 (en) 2004-12-29
NZ543446A (en) 2008-06-30
HUE030962T2 (en) 2017-06-28
EP1631663B1 (en) 2016-08-24
JP2007518395A (ja) 2007-07-12
JP5695020B2 (ja) 2015-04-01
ZA200510309B (en) 2006-08-30
MX342639B (es) 2016-10-07
UA92132C2 (ru) 2010-10-11
KR100908757B1 (ko) 2009-07-22
EA012965B1 (ru) 2010-02-26
IL238584A0 (en) 2015-06-30
CA2525953A1 (en) 2004-12-29
IL171831A (en) 2015-05-31
NO20056074L (no) 2006-03-22
US20050003349A1 (en) 2005-01-06
IL238584B (en) 2020-06-30
EA200501890A1 (ru) 2006-06-30
HK1082769A1 (zh) 2006-06-16
AU2004249133B2 (en) 2009-05-28
EP1631663A2 (en) 2006-03-08
JP5215561B2 (ja) 2013-06-19
KR20060016095A (ko) 2006-02-21
CN1826407A (zh) 2006-08-30
BRPI0410702B1 (pt) 2022-04-12
CA2525953C (en) 2023-10-10
ES2593082T3 (es) 2016-12-05
US8475806B2 (en) 2013-07-02
JP2013059346A (ja) 2013-04-04
AU2004249133A1 (en) 2004-12-29
NO341506B1 (no) 2017-11-27
CN1826407B (zh) 2013-09-11
WO2004112831A3 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
BRPI0410702A (pt) polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor
BR0009580A (pt) Composição, processos para preparar vìrus da influenza, para preparar um veìculo de liberação de genes, para preparar vìrus da influenza defeituosos de replicação infecciosa, para imunizar um paciente contra um patógeno, para preparar vìrus infeccioso, e para preparar vìrus, vìrus, célula, vetor, célula hospedeira, e, uso do vìrus
EP3294326B1 (en) Prime-boost regimens involving administration of at least one mrna construct
MA52645B1 (fr) Vaccins contre le virus respiratoire
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
WO2008068631A8 (en) Vaccines including antigen from four strains of influenza virus
MX2020004777A (es) Plataformas de suministro dirigido por crispr.
SV2007002202A (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan ref. pc32310a
HRP20220924T1 (hr) Imunoterapija zasnovana na pd-l1
WO2007126810A3 (en) High titer recombinant influenza viruses for vaccines
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
MY172421A (en) Immunostimulatory oligonucleotides
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
AR048596A1 (es) Atenuacion sinergica del virus de estomatitis vesiculosa, sus vectores y sus composiciones inmunogenas
BRPI0312173B8 (pt) vetor e processo para a preparação de partículas infecciosas de vírus do sarampo
Dorfmeier et al. Reinvestigating the role of IgM in rabies virus postexposure vaccination
MX2021005462A (es) Lipidos cationicos que contienen silicio.
PH12017501257A1 (en) Foot-and-mouth disease vaccine
BRPI0920622A8 (pt) vacina contra o vírus da doença equina africana
Kaur et al. Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge
Saxena et al. A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
CN116917266A (zh) 可离子化脂质及其制造和使用方法
AR034771A1 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25I Requirement for requested change of headquarter

Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION (US)

Free format text: A FIM DE ATENDER A ALTERACAO DE ENDERECO REQUERIDA ATRAVES DA PETICAO NO 870180056720 DE 29/06/2018, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO EO NOME DA EMPRESA QUE TEVE SEU ENDERECO ALTERADO.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25H Request for change of headquarter rejected

Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION (US)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870180056720 DE 29/06/2018, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2488, DE 11/09/2018.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/05/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2829 DE 25/03/2025 POR TER SIDO INDEVIDA.